Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H4GU
|
|||
| Drug Name |
EPX-200
|
|||
| Indication | Dravet syndrome [ICD-11: 8A61.11] | Phase 2 | [1] | |
| Company |
Epygenix Therapeutics Paramus, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT receptor (5HTR) | Target Info | Modulator | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.